Table of Content

1 INTRODUCTION 33
1.1 STUDY OBJECTIVES 33
1.2 MARKET DEFINITION 33
1.3 STUDY SCOPE 34
1.3.1 MARKETS COVERED 34
1.3.2 INCLUSIONS AND EXCLUSIONS OF STUDY 35
1.3.3 YEARS CONSIDERED 35
1.3.4 CURRENCY CONSIDERED 36
1.4 STAKEHOLDERS 36
1.5 SUMMARY OF CHANGES 36
2 RESEARCH METHODOLOGY 37
2.1 RESEARCH DATA 37
2.1.1 SECONDARY DATA 38
2.1.1.1 Key data from secondary sources 39
2.1.2 PRIMARY DATA 40
2.1.2.1 Primary sources 40
2.1.2.2 Key data from primary sources 41
2.1.2.3 Key industry insights 42
2.1.2.4 Breakdown of primary interviews 43
2.2 MARKET SIZE ESTIMATION 43
2.2.1 BOTTOM-UP APPROACH 44
2.2.1.1 Approach 1: Company revenue estimation approach 44
2.2.1.2 Approach 2: Lab-based analysis 45
2.2.1.3 Approach 3: Drug class-based analysis 46
2.2.1.4 Approach 4: Presentations of companies and primary interviews 46
2.2.1.5 Growth forecast 47
2.2.1.6 CAGR projections 47
2.2.2 TOP-DOWN APPROACH 48
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 49
2.4 MARKET SHARE ASSESSMENT 50
2.5 RESEARCH ASSUMPTIONS 50
2.6 STUDY LIMITATIONS 50
2.7 GROWTH RATE ASSUMPTIONS 51
2.8 RISK ASSESSMENT 51
3 EXECUTIVE SUMMARY 52
?
4 PREMIUM INSIGHTS 58
4.1 THERAPEUTIC DRUG MONITORING MARKET OVERVIEW 58
4.2 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET SHARE,
BY DRUG CLASS AND COUNTRY (2023) 59
4.3 THERAPEUTIC DRUG MONITORING MARKET, BY KEY COUNTRY 60
4.4 THERAPEUTIC DRUG MONITORING MARKET: REGIONAL MIX, 2024–2029 61
4.5 THERAPEUTIC DRUG MONITORING MARKET: DEVELOPING VS. DEVELOPED MARKETS 62
5 MARKET OVERVIEW 63
5.1 INTRODUCTION 63
5.2 MARKET DYNAMICS 64
5.2.1 DRIVERS 64
5.2.1.1 Importance of therapeutic drug monitoring in
organ transplant procedures 64
5.2.1.2 Use of therapeutic drug monitoring across various therapeutic fields 65
5.2.1.3 Increasing preference for precision medicine 67
5.2.1.4 Growing focus on R&D related to therapeutic drug monitoring 68
5.2.1.5 Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis 69
5.2.1.6 Increasing prevalence of epilepsy 70
5.2.1.7 Rising prevalence of cancer 71
5.2.2 RESTRAINTS 72
5.2.2.1 High capital investments 72
5.2.2.2 Reluctance of small hospitals to offer therapeutic
drug monitoring services 73
5.2.3 OPPORTUNITIES 73
5.2.3.1 Significant opportunities in BRICS countries 73
5.2.3.2 Innovations in immunoassay technologies to improve accuracy and speed of drug monitoring 74
5.2.3.3 Integration of AI and machine learning 75
5.2.4 CHALLENGES 76
5.2.4.1 Alternatives to conventional therapeutic drug monitoring 76
5.2.4.2 Operational challenges and inadequate infrastructure to restrict
TDM testing in low- and middle-income countries 76
5.2.4.3 Shortage of skilled professionals 77
5.3 PRICING ANALYSIS 77
5.4 VALUE CHAIN ANALYSIS 79
5.5 SUPPLY CHAIN ANALYSIS 80
5.6 ECOSYSTEM ANALYSIS 81
5.7 REGULATORY LANDSCAPE 82
5.7.1 NORTH AMERICA 86
5.7.1.1 US 86
5.7.1.2 Canada 87
5.7.2 EUROPE 88
5.7.3 ASIA PACIFIC 88
5.7.3.1 China 88
5.7.3.2 Japan 89
5.7.3.3 India 89
5.7.4 LATIN AMERICA 90
5.7.5 MIDDLE EAST 90
5.7.6 AFRICA 90
5.8 TRADE ANALYSIS 91
5.9 PATENT ANALYSIS 92
5.10 KEY CONFERENCES AND EVENTS IN 2025 AND 2026 93
5.11 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 94
5.12 TECHNOLOGY ANALYSIS 95
5.12.1 KEY TECHNOLOGY 95
5.12.1.1 Enzyme-linked immunosorbent assay 95
5.12.2 COMPLEMENTARY TECHNOLOGY 96
5.12.2.1 Liquid chromatography-mass spectrometry 96
5.12.3 ADJACENT TECHNOLOGY 96
5.12.3.1 Electrophoresis 96
5.13 PORTER’S FIVE FORCES ANALYSIS 97
5.13.1 THREAT OF NEW ENTRANTS 98
5.13.2 INTENSITY OF COMPETITIVE RIVALRY 98
5.13.3 BARGAINING POWER OF BUYERS 98
5.13.4 BARGAINING POWER OF SUPPLIERS 98
5.13.5 THREAT OF SUBSTITUTES 98
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 99
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 99
5.14.2 BUYING CRITERIA 99
5.15 INVESTMENT AND FUNDING SCENARIO 100
5.16 IMPACT OF GENERATIVE ARTIFICIAL INTELLIGENCE (AI) ON THERAPEUTIC
DRUG MONITORING MARKET 100
6 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT 102
6.1 INTRODUCTION 103
6.2 CONSUMABLES 103
6.2.1 REPEAT PURCHASES AND HIGH USAGE TO DRIVE MARKET 103
6.3 EQUIPMENT 105
6.3.1 IMMUNOASSAY ANALYZERS 108
6.3.1.1 High efficiency to drive adoption 108
6.3.2 CHROMATOGRAPHY & MS DETECTORS 111
6.3.2.1 Technological advancements to propel growth 111
?
6.3.3 CLINICAL CHEMISTRY ANALYZERS 114
6.3.3.1 Increasing incidence of chronic and complex diseases to
drive market 114
7 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY 117
7.1 INTRODUCTION 118
7.2 IMMUNOASSAYS 118
7.2.1 ENZYME-LINKED IMMUNOSORBENT ASSAYS 121
7.2.1.1 Accurate measurement of target-specific proteins to drive market 121
7.2.2 CHEMILUMINESCENCE IMMUNOASSAYS 123
7.2.2.1 Rapid detection time and good specificity to support growth 123
7.2.3 FLUORESCENCE IMMUNOASSAYS 127
7.2.3.1 High operability and better sensitivity of FIAs to drive market 127
7.2.4 COLORIMETRIC IMMUNOASSAYS 130
7.2.4.1 Demand for colorimetric immunoassays to decline due to rising preference for advanced equipment 130
7.2.5 OTHER IMMUNOASSAYS 132
7.3 CHROMATOGRAPHY-MS 134
7.3.1 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY 137
7.3.1.1 High accuracy to drive demand for LC-MS 137
7.3.2 GAS CHROMATOGRAPHY-MASS SPECTROMETRY 140
7.3.2.1 Drawbacks of GC-MS to challenge market growth 140
7.4 OTHER TECHNOLOGIES 142
8 THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS 146
8.1 INTRODUCTION 147
8.2 ANTIEPILEPTIC DRUGS 147
8.2.1 HIGH COMPLEXITY AND HETEROGENEITY OF EPILEPSY TO DRIVE GROWTH 147
8.3 ANTIARRHYTHMIC DRUGS 150
8.3.1 INCREASING INCIDENCE OF HEART DISORDERS TO BOOST DEMAND 150
8.4 IMMUNOSUPPRESSANT DRUGS 154
8.4.1 INCREASING NUMBER OF ORGAN TRANSPLANTATION
PROCEDURES TO DRIVE MARKET 154
8.5 ANTIBIOTIC DRUGS 157
8.5.1 TECHNOLOGICAL ADVANCEMENTS TO PROPEL DEMAND 157
8.6 BRONCHODILATOR DRUGS 160
8.6.1 RISING PREVALENCE OF RESPIRATORY DISEASES TO ENSURE DEMAND
FOR BRONCHODILATOR DRUG MONITORING 160
8.7 PSYCHOACTIVE DRUGS 163
8.7.1 RISING CASES OF MENTAL ILLNESS TO AUGMENT MARKET GROWTH 163
8.8 OTHER DRUGS 166
?
9 THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA 170
9.1 INTRODUCTION 171
9.2 NEUROLOGICAL DISORDERS 171
9.2.1 INCREASING PREVALENCE OF NEUROLOGICAL DISORDERS TO
PROPEL MARKET 171
9.3 CARDIOLOGY 174
9.3.1 HIGH BURDEN OF CARDIOVASCULAR DISEASES TO DRIVE MARKET 174
9.4 INFECTIOUS DISEASES 176
9.4.1 INCREASING PREVALENCE OF TB AND HEPATITIS TO BOOST DEMAND 176
9.5 ONCOLOGY 179
9.5.1 RISING BURDEN OF CANCER AND GROWING EMPHASIS ON PERSONALIZED MEDICINE TO PROPEL MARKET 179
9.6 OTHER THERAPEUTIC AREAS 182
10 THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN 185
10.1 INTRODUCTION 186
10.2 BLOOD 186
10.2.1 INNOVATIONS IN BLOOD SAMPLING TECHNIQUES TO DRIVE MARKET 186
10.3 SALIVA 188
10.3.1 DEVELOPMENTS IN IMMUNOASSAY-BASED SALIVA TESTS TO DRIVE MARKET 188
10.4 OTHER SAMPLES 190
11 THERAPEUTIC DRUG MONITORING MARKET, BY END USER 193
11.1 INTRODUCTION 194
11.2 HOSPITAL LABORATORIES 194
11.2.1 INCREASING NUMBER OF SPECIALTY DIAGNOSTIC TESTS
PERFORMED TO DRIVE MARKET 194
11.3 COMMERCIAL & PRIVATE LABORATORIES 197
11.3.1 EXTENSIVE TEST MENU OF COMMERCIAL & PRIVATE LABS TO SUSTAIN DEMAND FOR SERVICES 197
11.4 OTHER END USERS 199
12 THERAPEUTIC DRUG MONITORING MARKET, BY REGION 202
12.1 INTRODUCTION 203
12.2 NORTH AMERICA 203
12.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK 204
12.2.2 US 210
12.2.2.1 Increasing awareness regarding precision medicine to propel market 210
12.2.3 CANADA 215
12.2.3.1 Availability of funding for research to offer growth opportunities 215
?
12.3 EUROPE 220
12.4 EUROPE: MACROECONOMIC OUTLOOK 221
12.4.1 GERMANY 226
12.4.1.1 Rising prevalence of chronic medical conditions such as cancer and diabetes to support market growth 226
12.4.2 UK 230
12.4.2.1 Increasing cases of chronic diseases to drive market 230
12.4.3 FRANCE 235
12.4.3.1 Rising awareness of benefits of therapeutic drug monitoring to accelerate demand 235
12.4.4 ITALY 239
12.4.4.1 Rising incidence of cancer to drive demand 239
12.4.5 SPAIN 244
12.4.5.1 Adoption of technologically advanced immunoassays to
boost market 244
12.4.6 REST OF EUROPE 249
12.5 ASIA PACIFIC 253
12.6 ASIA PACIFIC: MACROECONOMIC OUTLOOK 253
12.6.1 JAPAN 259
12.6.1.1 High prevalence of chronic diseases and advanced healthcare infrastructure to drive market 259
12.6.2 CHINA 264
12.6.2.1 Rising number of organ transplants to boost market 264
12.6.3 INDIA 268
12.6.3.1 Rising incidence of cancer to propel market 268
12.6.4 AUSTRALIA 273
12.6.4.1 High healthcare expenditure and favorable government
initiatives to propel market 273
12.6.5 REST OF ASIA PACIFIC 278
12.7 LATIN AMERICA 282
12.7.1 INCREASING BURDEN OF CHRONIC CONDITIONS AND EXPANDING HEALTHCARE INFRASTRUCTURE TO PROPEL MARKET 282
12.7.2 LATIN AMERICA: MACROECONOMIC OUTLOOK 284
12.8 MIDDLE EAST & AFRICA 288
12.8.1 INCREASING NUMBER OF CANCER PATIENTS TO DRIVE MARKET 288
12.8.2 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK 290
12.9 GCC COUNTRIES 294
12.9.1 GROWING HEALTHCARE INFRASTRUCTURE TO FUEL MARKET GROWTH 294
12.9.2 GCC COUNTRIES: MACROECONOMIC OUTLOOK 296
?
13 COMPETITIVE LANDSCAPE 301
13.1 OVERVIEW 301
13.2 RIGHT TO WIN 301
13.3 STRATEGIES ADOPTED BY KEY PLAYERS 301
13.4 REVENUE ANALYSIS 303
13.5 MARKET SHARE ANALYSIS 304
13.6 COMPANY EVALUATION MATRIX: KEY PLAYERS 305
13.6.1 STARS 306
13.6.2 EMERGING LEADERS 306
13.6.3 PERVASIVE PLAYERS 306
13.6.4 PARTICIPANTS 306
13.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 308
13.6.5.1 Company footprint 308
13.6.5.2 Region footprint 308
13.6.5.3 Product footprint 309
13.6.5.4 Technology footprint 309
13.6.5.5 End-user footprint 310
13.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES 310
13.7.1 PROGRESSIVE COMPANIES 310
13.7.2 RESPONSIVE COMPANIES 310
13.7.3 DYNAMIC COMPANIES 311
13.7.4 STARTING BLOCKS 311
13.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 312
13.7.5.1 Detailed list of key startups/SMEs 312
13.8 COMPANY VALUATION & FINANCIAL METRICS 312
13.8.1 FINANCIAL METRICS 312
13.8.2 COMPANY VALUATION 313
13.9 PRODUCT/BRAND COMPARISON 313
13.10 COMPETITIVE SCENARIO 314
13.10.1 PRODUCT LAUNCHES 314
13.10.2 DEALS 315
13.10.3 EXPANSIONS 315
14 COMPANY PROFILES 316
14.1 KEY PLAYERS 316
14.1.1 ABBOTT 316
14.1.1.1 Business overview 316
14.1.1.2 Products offered 317
14.1.1.3 MnM view 318
14.1.1.3.1 Key strengths 318
14.1.1.3.2 Strategic choices 318
14.1.1.3.3 Weaknesses and competitive threats 318
14.1.2 THERMO FISHER SCIENTIFIC INC. 319
14.1.2.1 Business overview 319
14.1.2.2 Products offered 320
14.1.2.3 Recent developments 322
14.1.2.3.1 Product launches 322
14.1.2.3.2 Deals 322
14.1.2.4 MnM view 323
14.1.2.4.1 Key strengths 323
14.1.2.4.2 Strategic choices 323
14.1.2.4.3 Weaknesses and competitive threats 323
14.1.3 F. HOFFMANN-LA ROCHE LTD. 324
14.1.3.1 Business overview 324
14.1.3.2 Products offered 326
14.1.3.3 Recent developments 327
14.1.3.3.1 Product launches 327
14.1.3.3.2 Deals 327
14.1.3.4 MnM view 327
14.1.3.4.1 Key strengths 327
14.1.3.4.2 Strategic choices 327
14.1.3.4.3 Weaknesses and competitive threats 327
14.1.4 SIEMENS HEALTHINEERS AG 328
14.1.4.1 Business overview 328
14.1.4.2 Products offered 330
14.1.4.3 Recent developments 331
14.1.4.3.1 Product launches 331
14.1.4.3.2 Deals 332
14.1.4.4 MnM view 332
14.1.4.4.1 Key strengths 332
14.1.4.4.2 Strategic choices 332
14.1.4.4.3 Weaknesses and competitive threats 332
14.1.5 DANAHER CORPORATION 333
14.1.5.1 Business overview 333
14.1.5.2 Products offered 334
14.1.5.3 Recent developments 335
14.1.5.3.1 Product launches 335
14.1.5.3.2 Deals 336
14.1.5.4 MnM view 336
14.1.5.4.1 Key strengths 336
14.1.5.4.2 Strategic choices 336
14.1.5.4.3 Weaknesses and competitive threats 337
?
14.1.6 BIO-RAD LABORATORIES, INC. 338
14.1.6.1 Business overview 338
14.1.6.2 Products offered 339
14.1.6.3 Recent developments 341
14.1.6.3.1 Product launches 341
14.1.6.3.2 Deals 341
14.1.7 BIOM?RIEUX SA 342
14.1.7.1 Business overview 342
14.1.7.2 Products offered 344
14.1.8 BIOSYNEX SA 345
14.1.8.1 Business overview 345
14.1.8.2 Products offered 346
14.1.8.3 Recent developments 347
14.1.8.3.1 Product launches 347
14.1.8.3.2 Deals 347
14.1.9 GRIFOLS, S.A. 348
14.1.9.1 Business overview 348
14.1.9.2 Products offered 350
14.1.9.3 Recent developments 350
14.1.9.3.1 Deals 350
14.1.10 EXAGEN INC. 351
14.1.10.1 Business overview 351
14.1.10.2 Products offered 352
14.1.10.3 Recent developments 352
14.1.10.3.1 Deals 352
14.1.11 ARK DIAGNOSTICS, INC. 353
14.1.11.1 Business overview 353
14.1.11.2 Products offered 353
14.1.12 R-BIOPHARM AG 355
14.1.12.1 Business overview 355
14.1.12.2 Products offered 355
14.1.12.3 Recent developments 356
14.1.12.3.1 Product launches 356
14.1.13 RANDOX LABORATORIES LTD. 357
14.1.13.1 Business overview 357
14.1.13.2 Products offered 357
14.2 OTHER PLAYERS 359
14.2.1 APDIA GROUP 359
14.2.2 BBI SOLUTIONS 359
14.2.3 EAGLE BIOSCIENCES, INC. 360
14.2.4 JASEM LABORATORY SYSTEMS AND SOLUTIONS 362
14.2.5 AALTO SCIENTIFIC, LTD. 362
14.2.6 IMMUNDIAGNOSTIK AG 363
14.2.7 UTAK 364
14.2.8 SEKISUI MEDICAL CO., LTD. 365
14.2.9 DIASYSTEM SCANDINAVIA AB 366
14.2.10 CAMBRIDGE LIFE SCIENCES LIMITED 367
14.2.11 CHROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH 367
14.2.12 B?HLMANN LABORATORIES AG 368
14.2.13 SJK GLOBAL, LLC 368
14.2.14 EPITOPE DIAGNOSTICS, INC. 369
14.2.15 QED BIOSCIENCE INC. 369
14.2.16 BODITECH MED INC. 370
14.2.17 IMMUNODIAGNOSTIC SYSTEMS 371
15 APPENDIX 372
15.1 DISCUSSION GUIDE 372
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 377
15.3 CUSTOMIZATION OPTIONS 379
15.4 RELATED REPORTS 379
15.5 AUTHOR DETAILS 380



List of Figures

FIGURE 1 THERAPEUTIC DRUG MONITORING MARKET SEGMENTATION 34
FIGURE 2 THERAPEUTIC DRUG MONITORING MARKET: RESEARCH DESIGN 37
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND
DEMAND-SIDE PARTICIPANTS 43
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE DESIGNATION, AND REGION 43
FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 44
FIGURE 6 ESTIMATING GLOBAL THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS 46
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 47
FIGURE 8 TOP-DOWN APPROACH 48
FIGURE 9 DATA TRIANGULATION 49
FIGURE 10 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT 2024 VS. 2029 (USD MILLION) 52
FIGURE 11 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY 2024 VS. 2029 (USD MILLION) 53
FIGURE 12 THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS 2024 VS. 2029 (USD MILLION) 54
FIGURE 13 THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA 2024 VS. 2029 (USD MILLION) 55
FIGURE 14 THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN 2024 VS. 2029 (USD MILLION) 55
FIGURE 15 THERAPEUTIC DRUG MONITORING MARKET, BY END USER 2024 VS. 2029 (USD MILLION) 56
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF THERAPEUTIC DRUG MONITORING MARKET 57
FIGURE 17 RISING PREFERENCE FOR PRECISION MEDICINE TO DRIVE MARKET 58
FIGURE 18 ANTIEPILEPTIC DRUGS ACCOUNTED FOR LARGEST SHARE OF
ASIA PACIFIC MARKET IN 2023 59
FIGURE 19 CHINA TO REGISTER HIGHEST GROWTH FROM 2024 TO 2029 60
FIGURE 20 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 61
FIGURE 21 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH
DURING FORECAST PERIOD 62
FIGURE 22 THERAPEUTIC DRUG MONITORING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 64
FIGURE 23 UK: NUMBER OF DECEASED DONORS AND TRANSPLANTS APRIL 1, 2020–MARCH 31, 2024 65
FIGURE 24 PERSONALIZED MEDICINE APPROVALS BY US FDA, 2015–2022 67
FIGURE 25 NUMBER OF RESEARCH PUBLICATIONS ON THERAPEUTIC
DRUG MONITORING, 2015–2021 68
FIGURE 26 INCIDENCE OF DIABETES, BY REGION, 2021 VS. 2030 VS. 2045 (MILLION) 69
FIGURE 27 NUMBER OF US ADULTS WITH ACTIVE EPILEPSY, BY AGE GROUP (THOUSAND) 71
FIGURE 28 INCIDENCE OF CANCER, BY REGION, 2022 VS. 2030 VS. 2045 (MILLION) 72
FIGURE 29 GROWTH IN CURRENT HEALTHCARE EXPENDITURE PER CAPITA IN
BRICS COUNTRIES, 2014–2021 74
FIGURE 30 VALUE CHAIN ANALYSIS: MAJOR VALUE-ADDED DURING MANUFACTURING
AND ASSEMBLY PHASES 79
FIGURE 31 DIRECT DISTRIBUTION?PREFERRED STRATEGY FOR PROMINENT COMPANIES 81
FIGURE 32 THERAPEUTIC DRUG MONITORING MARKET: ECOSYSTEM ANALYSIS 81
FIGURE 33 PATENT ANALYSIS FOR THERAPEUTIC DRUG MONITORING JANUARY 2015–DECEMBER 2023 92
FIGURE 34 REVENUE SHIFT FOR THERAPEUTIC DRUG MONITORING 94
FIGURE 35 THERAPEUTIC DRUG MONITORING MARKET: PORTER’S FIVE FORCES ANALYSIS 97
FIGURE 36 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS 99
FIGURE 37 KEY BUYING CRITERIA FOR END USERS 99
FIGURE 38 INVESTMENT AND FUNDING SCENARIO 100
FIGURE 39 US: PATIENTS ON WAITING LIST VS. TRANSPLANTS PERFORMED, BY ORGAN, 2023 155
FIGURE 40 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET SNAPSHOT 205
FIGURE 41 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET SNAPSHOT 254
FIGURE 42 THERAPEUTIC DRUG MONITORING MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2021–2023 (USD BILLION) 303
FIGURE 43 THERAPEUTIC DRUG MONITORING MARKET SHARE ANALYSIS, 2023 304
FIGURE 44 THERAPEUTIC DRUG MONITORING MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2023 307
FIGURE 45 THERAPEUTIC DRUG MONITORING MARKET: COMPANY FOOTPRINT 308
FIGURE 46 THERAPEUTIC DRUG MONITORING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 311
FIGURE 47 EV/EBITDA OF KEY VENDORS 312
FIGURE 48 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 313
FIGURE 49 THERAPEUTIC DRUG MONITORING MARKET: BRAND/PRODUCT
COMPARATIVE ANALYSIS 313
FIGURE 50 ABBOTT: COMPANY SNAPSHOT (2023) 317
FIGURE 51 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023) 320
FIGURE 52 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023) 325
FIGURE 53 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2023) 329
FIGURE 54 DANAHER CORPORATION: COMPANY SNAPSHOT (2023) 334
FIGURE 55 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2023) 339
FIGURE 56 BIOM?RIEUX SA: COMPANY SNAPSHOT (2023) 343
FIGURE 57 BIOSYNEX SA: COMPANY SNAPSHOT (2023) 345
FIGURE 58 GRIFOLS, S.A.: COMPANY SNAPSHOT (2023) 349
FIGURE 59 EXAGEN INC.: COMPANY SNAPSHOT (2023) 351

List of Tables

TABLE 1 RISK ASSESSMENT: THERAPEUTIC DRUG MONITORING MARKET 51
TABLE 2 CLASSES OF DRUGS THAT REQUIRE MONITORING 66
TABLE 3 GLOBAL INCIDENCE OF INFECTIOUS DISEASES 70
TABLE 4 AVERAGE SELLING PRICE OF THERAPEUTIC DRUG MONITORING PRODUCTS BY TYPE 78
TABLE 5 AVERAGE SELLING PRICE OF THERAPEUTIC DRUG MONITORING PRODUCTS BY KEY PLAYER, 2022–2024 78
TABLE 6 AVERAGE SELLING PRICE OF THERAPEUTIC DRUG MONITORING PRODUCTS BY KEY REGION 79
TABLE 7 THERAPEUTIC DRUG MONITORING MARKET: ROLE OF COMPANIES IN ECOSYSTEM 82
TABLE 8 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 83
TABLE 9 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 84
TABLE 10 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 85
TABLE 11 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 85
TABLE 12 IMPORT DATA FOR INSTRUMENTS AND APPARATUS USED IN PHYSICAL
AND CHEMICAL ANALYSIS, BY COUNTRY, 2019–2023 (USD MILLION) 91
TABLE 13 EXPORT DATA FOR INSTRUMENTS AND APPARATUS USED IN PHYSICAL
AND CHEMICAL ANALYSIS, BY COUNTRY, 2019–2023 (USD MILLION) 91
TABLE 14 LIST OF CONFERENCES AND EVENTS, 2025–2026 93
TABLE 15 THERAPEUTIC DRUG MONITORING MARKET: PORTER’S FIVE FORCES ANALYSIS 97
TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS (%) 99
TABLE 17 KEY BUYING CRITERIA FOR END USERS 100
TABLE 18 AI APPLICATIONS IN THERAPEUTIC DRUG MONITORING 101
TABLE 19 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT 2022–2029 (USD MILLION) 103
TABLE 20 THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET, BY REGION 2022–2029 (USD MILLION) 104
TABLE 21 NORTH AMERICA: THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET BY COUNTRY, 2022–2029 (USD MILLION) 104
TABLE 22 EUROPE: THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET BY COUNTRY, 2022–2029 (USD MILLION) 105
TABLE 23 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET BY COUNTRY, 2022–2029 (USD MILLION) 105
TABLE 24 DRUGS MONITORED USING ANALYTICAL EQUIPMENT 106
TABLE 25 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE 2022–2029 (USD MILLION) 106
TABLE 26 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY REGION 2022–2029 (USD MILLION) 107
TABLE 27 NORTH AMERICA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET BY COUNTRY, 2022–2029 (USD MILLION) 107
TABLE 28 EUROPE: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 108
TABLE 29 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET BY COUNTRY, 2022–2029 (USD MILLION) 108
TABLE 30 THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAY ANALYZERS BY REGION, 2022–2029 (USD MILLION) 109
TABLE 31 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAY ANALYZERS, BY COUNTRY, 2022–2029 (USD MILLION) 110
TABLE 32 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAY ANALYZERS, BY COUNTRY, 2022–2029 (USD MILLION) 110
TABLE 33 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAY ANALYZERS, BY COUNTRY, 2022–2029 (USD MILLION) 110
TABLE 34 CHROMATOGRAPHY & MS DETECTORS: PRODUCT LAUNCHES BY COMPANY, 2020–2024 111
TABLE 35 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY &
MS DETECTORS, BY REGION, 2022–2029 (USD MILLION) 112
TABLE 36 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY & MS DETECTORS, BY COUNTRY, 2022–2029 (USD MILLION) 112
TABLE 37 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY & MS DETECTORS, BY COUNTRY, 2022–2029 (USD MILLION) 113
TABLE 38 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY & MS DETECTORS, BY COUNTRY, 2022–2029 (USD MILLION) 113
TABLE 39 THERAPEUTIC DRUG MONITORING MARKET FOR CLINICAL CHEMISTRY ANALYZERS, BY REGION, 2022–2029 (USD MILLION) 114
TABLE 40 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CLINICAL CHEMISTRY ANALYZERS, BY COUNTRY, 2022–2029 (USD MILLION) 115
TABLE 41 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CLINICAL CHEMISTRY ANALYZERS, BY COUNTRY, 2022–2029 (USD MILLION) 115
TABLE 42 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CLINICAL CHEMISTRY ANALYZERS, BY COUNTRY, 2022–2029 (USD MILLION) 116
TABLE 43 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY 2022–2029 (USD MILLION) 118
TABLE 44 THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION) 119
TABLE 45 THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY REGION, 2022–2029 (USD MILLION) 119
TABLE 46 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION) 120
TABLE 47 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS BY COUNTRY, 2022–2029 (USD MILLION) 120
TABLE 48 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION) 120
TABLE 49 THERAPEUTIC DRUG MONITORING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY REGION, 2022–2029 (USD MILLION) 122
TABLE 50 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022–2029 (USD MILLION) 122
TABLE 51 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022–2029 (USD MILLION) 123
TABLE 52 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2022–2029 (USD MILLION) 123
TABLE 53 EXAMPLES OF CLIA SYSTEMS 124
TABLE 54 LIST OF COMPOUNDS ANALYZED BY CHEMILUMINESCENCE IMMUNOASSAYS 124
TABLE 55 THERAPEUTIC DRUG MONITORING MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY REGION, 2022–2029 (USD MILLION) 125
TABLE 56 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY 2022–2029 (USD MILLION) 125
TABLE 57 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION) 126
TABLE 58 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY 2022–2029 (USD MILLION) 126
TABLE 59 LIST OF COMPOUNDS ANALYZED BY FLUORESCENCE
POLARIZATION IMMUNOASSAYS 127
TABLE 60 THERAPEUTIC DRUG MONITORING MARKET FOR FLUORESCENCE IMMUNOASSAYS, BY REGION, 2022–2029 (USD MILLION) 128
TABLE 61 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR FLUORESCENCE IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION) 128
TABLE 62 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR FLUORESCENCE IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION) 129
TABLE 63 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR FLUORESCENCE IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION) 129
TABLE 64 THERAPEUTIC DRUG MONITORING MARKET FOR COLORIMETRIC IMMUNOASSAYS, BY REGION, 2022–2029 (USD MILLION) 130
TABLE 65 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR COLORIMETRIC IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION) 131
TABLE 66 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR COLORIMETRIC IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION) 131
TABLE 67 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR COLORIMETRIC IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION) 132
TABLE 68 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER IMMUNOASSAYS BY REGION, 2022–2029 (USD MILLION) 133
TABLE 69 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION) 133
TABLE 70 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION) 134
TABLE 71 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION) 134
TABLE 72 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022–2029 (USD MILLION) 135
TABLE 73 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS BY REGION, 2022–2029 (USD MILLION) 136
TABLE 74 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY COUNTRY, 2022–2029 (USD MILLION) 136
TABLE 75 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY COUNTRY, 2022–2029 (USD MILLION) 137
TABLE 76 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY COUNTRY, 2022–2029 (USD MILLION) 137
TABLE 77 THERAPEUTIC DRUG MONITORING MARKET FOR LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY, BY REGION, 2022–2029 (USD MILLION) 138
TABLE 78 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR
LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY, BY COUNTRY 2022–2029 (USD MILLION) 139
TABLE 79 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY, BY COUNTRY 2022–2029 (USD MILLION) 139
TABLE 80 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY, BY COUNTRY 2022–2029 (USD MILLION) 140
TABLE 81 THERAPEUTIC DRUG MONITORING MARKET FOR GAS CHROMATOGRAPHY-MASS SPECTROMETRY, BY REGION, 2022–2029 (USD MILLION) 141
TABLE 82 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR GAS CHROMATOGRAPHY-MASS SPECTROMETRY, BY COUNTRY 2022–2029 (USD MILLION) 141
TABLE 83 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR GAS CHROMATOGRAPHY-MASS SPECTROMETRY, BY COUNTRY 2022–2029 (USD MILLION) 142
TABLE 84 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR GAS CHROMATOGRAPHY-MASS SPECTROMETRY, BY COUNTRY 2022–2029 (USD MILLION) 142
TABLE 85 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER TECHNOLOGIES BY REGION, 2022–2029 (USD MILLION) 143
TABLE 86 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION) 144
TABLE 87 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION) 144
TABLE 88 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION) 145
TABLE 89 THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS 2022–2029 (USD MILLION) 147
TABLE 90 DOSAGE GUIDELINES FOR NEW ANTIEPILEPTIC DRUGS IN
ADOLESCENTS AND ADULTS 148
TABLE 91 THERAPEUTIC DRUG MONITORING: LIMITATIONS FACED IN
NEW ANTIEPILEPTIC DRUGS 149
TABLE 92 THERAPEUTIC DRUG MONITORING MARKET FOR ANTIEPILEPTIC DRUGS BY REGION, 2022–2029 (USD MILLION) 149
TABLE 93 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIEPILEPTIC DRUGS, BY COUNTRY, 2022–2029 (USD MILLION) 149
TABLE 94 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIEPILEPTIC DRUGS, BY COUNTRY, 2022–2029 (USD MILLION) 150
TABLE 95 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIEPILEPTIC DRUGS, BY COUNTRY, 2022–2029 (USD MILLION) 150
TABLE 96 CLASSIFICATION OF ANTIARRHYTHMIC THERAPIES 151
TABLE 97 THERAPEUTIC DRUG MONITORING MARKET FOR ANTIARRHYTHMIC DRUGS BY REGION, 2022–2029 (USD MILLION) 152
TABLE 98 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIARRHYTHMIC DRUGS, BY COUNTRY, 2022–2029 (USD MILLION) 152
TABLE 99 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIARRHYTHMIC DRUGS, BY COUNTRY, 2022–2029 (USD MILLION) 153
TABLE 100 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIARRHYTHMIC DRUGS, BY COUNTRY, 2022–2029 (USD MILLION) 153
TABLE 101 COMMONLY USED IMMUNOSUPPRESSANT DRUGS IN ORGAN TRANSPLANTS 154
TABLE 102 THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOSUPPRESSANT DRUGS, BY REGION, 2022–2029 (USD MILLION) 155
TABLE 103 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOSUPPRESSANT DRUGS, BY COUNTRY, 2022–2029 (USD MILLION) 156
TABLE 104 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOSUPPRESSANT DRUGS, BY COUNTRY, 2022–2029 (USD MILLION) 156
TABLE 105 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOSUPPRESSANT DRUGS, BY COUNTRY, 2022–2029 (USD MILLION) 157
TABLE 106 EXAMPLES OF ANTIBIOTIC DRUGS 157
TABLE 107 COMPARISON OF DIFFERENT TECHNOLOGIES FOR DETERMINING ANTIMICROBIAL LEVELS IN BIOFLUIDS 158
TABLE 108 THERAPEUTIC DRUG MONITORING MARKET FOR ANTIBIOTIC DRUGS, BY REGION, 2022–2029 (USD MILLION) 159
TABLE 109 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIBIOTIC DRUGS, BY COUNTRY, 2022–2029 (USD MILLION) 159
TABLE 110 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIBIOTIC DRUGS BY COUNTRY, 2022–2029 (USD MILLION) 160
TABLE 111 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR ANTIBIOTIC DRUGS, BY COUNTRY, 2022–2029 (USD MILLION) 160
TABLE 112 EXAMPLES OF BRONCHODILATOR DRUGS 161
TABLE 113 THERAPEUTIC DRUG MONITORING MARKET FOR BRONCHODILATOR DRUGS BY REGION, 2022–2029 (USD MILLION) 161
TABLE 114 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR BRONCHODILATOR DRUGS, BY COUNTRY, 2022–2029 (USD MILLION) 162
TABLE 115 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR BRONCHODILATOR DRUGS, BY COUNTRY, 2022–2029 (USD MILLION) 162
TABLE 116 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR BRONCHODILATOR DRUGS, BY COUNTRY, 2022–2029 (USD MILLION) 163
TABLE 117 EXAMPLES OF PSYCHOACTIVE DRUGS 164
TABLE 118 THERAPEUTIC DRUG MONITORING MARKET FOR PSYCHOACTIVE DRUGS BY REGION, 2022–2029 (USD MILLION) 164
TABLE 119 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR PSYCHOACTIVE DRUGS, BY COUNTRY, 2022–2029 (USD MILLION) 165
TABLE 120 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR PSYCHOACTIVE DRUGS, BY COUNTRY, 2022–2029 (USD MILLION) 165
TABLE 121 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR PSYCHOACTIVE DRUGS, BY COUNTRY, 2022–2029 (USD MILLION) 166
TABLE 122 EXAMPLES OF OTHER DRUGS 167
TABLE 123 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER DRUGS, BY REGION, 2022–2029 (USD MILLION) 167
TABLE 124 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER DRUGS, BY COUNTRY, 2022–2029 (USD MILLION) 168
TABLE 125 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER DRUGS BY COUNTRY, 2022–2029 (USD MILLION) 168
TABLE 126 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER DRUGS BY COUNTRY, 2022–2029 (USD MILLION) 169
TABLE 127 THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA 2022–2029 (USD MILLION) 171
TABLE 128 PREVALENCE OF NEUROLOGICAL DISORDERS 172
TABLE 129 THERAPEUTIC DRUG MONITORING MARKET FOR NEUROLOGICAL DISORDERS BY REGION, 2022–2029 (USD MILLION) 172
TABLE 130 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 173
TABLE 131 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 173
TABLE 132 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 174
TABLE 133 THERAPEUTIC DRUG MONITORING MARKET FOR CARDIOLOGY, BY REGION 2022–2029 (USD MILLION) 175
TABLE 134 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CARDIOLOGY, BY COUNTRY, 2022–2029 (USD MILLION) 175
TABLE 135 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CARDIOLOGY BY COUNTRY, 2022–2029 (USD MILLION) 176
TABLE 136 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CARDIOLOGY BY COUNTRY, 2022–2029 (USD MILLION) 176
TABLE 137 THERAPEUTIC DRUG MONITORING MARKET FOR INFECTIOUS DISEASES BY REGION, 2022–2029 (USD MILLION) 177
TABLE 138 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 178
TABLE 139 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 178
TABLE 140 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 179
TABLE 141 INCREASING INCIDENCE OF CANCER, BY REGION 2022 VS. 2030 VS. 2040 (MILLION) 180
TABLE 142 THERAPEUTIC DRUG MONITORING MARKET FOR ONCOLOGY, BY REGION 2022–2029 (USD MILLION) 180
TABLE 143 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR ONCOLOGY BY COUNTRY, 2022–2029 (USD MILLION) 181
TABLE 144 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR ONCOLOGY BY COUNTRY, 2022–2029 (USD MILLION) 181
TABLE 145 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR ONCOLOGY BY COUNTRY, 2022–2029 (USD MILLION) 182
TABLE 146 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER THERAPEUTIC AREAS BY REGION, 2022–2029 (USD MILLION) 183
TABLE 147 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION) 183
TABLE 148 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION) 184
TABLE 149 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION) 184
TABLE 150 THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN 2022–2029 (USD MILLION) 186
TABLE 151 THERAPEUTIC DRUG MONITORING MARKET FOR BLOOD SAMPLES, BY REGION, 2022–2029 (USD MILLION) 187
TABLE 152 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION) 187
TABLE 153 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR BLOOD SAMPLES BY COUNTRY, 2022–2029 (USD MILLION) 188
TABLE 154 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION) 188
TABLE 155 THERAPEUTIC DRUG MONITORING MARKET FOR SALIVA SAMPLES, BY REGION, 2022–2029 (USD MILLION) 189
TABLE 156 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR SALIVA SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION) 189
TABLE 157 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR SALIVA SAMPLES BY COUNTRY, 2022–2029 (USD MILLION) 190
TABLE 158 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR SALIVA SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION) 190
TABLE 159 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER SPECIMENS, BY REGION, 2022–2029 (USD MILLION) 191
TABLE 160 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION) 191
TABLE 161 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER SPECIMENS BY COUNTRY, 2022–2029 (USD MILLION) 192
TABLE 162 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022–2029 (USD MILLION) 192
TABLE 163 THERAPEUTIC DRUG MONITORING MARKET, BY END USER 2022–2029 (USD MILLION) 194
TABLE 164 THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL LABORATORIES BY REGION, 2022–2029 (USD MILLION) 195
TABLE 165 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 196
TABLE 166 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 196
TABLE 167 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 197
TABLE 168 THERAPEUTIC DRUG MONITORING MARKET FOR COMMERCIAL & PRIVATE LABORATORIES, BY REGION, 2022–2029 (USD MILLION) 198
TABLE 169 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR COMMERCIAL & PRIVATE LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 198
TABLE 170 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR COMMERCIAL & PRIVATE LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 199
TABLE 171 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR COMMERCIAL & PRIVATE LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION) 199
TABLE 172 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION) 200
TABLE 173 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION) 200
TABLE 174 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER END USERS BY COUNTRY, 2022–2029 (USD MILLION) 201
TABLE 175 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION) 201
TABLE 176 THERAPEUTIC DRUG MONITORING MARKET, BY REGION 2022–2029 (USD MILLION) 203
TABLE 177 NORTH AMERICA: KEY MACROINDICATORS 204
TABLE 178 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 206
TABLE 179 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 206
TABLE 180 NORTH AMERICA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET BY TYPE, 2022–2029 (USD MILLION) 206
TABLE 181 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 207
TABLE 182 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION) 207
TABLE 183 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022–2029 (USD MILLION) 208
TABLE 184 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022–2029 (USD MILLION) 208
TABLE 185 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 209
TABLE 186 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN, 2022–2029 (USD MILLION) 209
TABLE 187 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022–2029 (USD MILLION) 209
TABLE 188 FDA NOVEL DRUG THERAPY APPROVALS FOR 2023 210
TABLE 189 NUMBER OF TESTS COVERED BY MEDICARE FOR EACH DRUG CLASS 211
TABLE 190 US: NUMBER OF LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY TESTS 2022–2029 (MILLION) 212
TABLE 191 US: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT 2022–2029 (USD MILLION) 212
TABLE 192 US: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE 2022–2029 (USD MILLION) 212
TABLE 193 US: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY 2022–2029 (USD MILLION) 213
TABLE 194 US: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION) 213
TABLE 195 US: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS BY TYPE, 2022–2029 (USD MILLION) 213
TABLE 196 US: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS 2022–2029 (USD MILLION) 214
TABLE 197 US: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA 2022–2029 (USD MILLION) 214
TABLE 198 US: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN 2022–2029 (USD MILLION) 215
TABLE 199 US: THERAPEUTIC DRUG MONITORING MARKET, BY END USER 2022–2029 (USD MILLION) 215
TABLE 200 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT 2022–2029 (USD MILLION) 216
TABLE 201 CANADA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION) 217
TABLE 202 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY 2022–2029 (USD MILLION) 217
TABLE 203 CANADA: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS BY TYPE, 2022–2029 (USD MILLION) 217
TABLE 204 CANADA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022–2029 (USD MILLION) 218
TABLE 205 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS 2022–2029 (USD MILLION) 218
TABLE 206 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 219
TABLE 207 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN 2022–2029 (USD MILLION) 219
TABLE 208 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER 2022–2029 (USD MILLION) 219
TABLE 209 EUROPE: CANCER INCIDENCE, BY TYPE, 2022 VS. 2030 220
TABLE 210 EUROPE: KEY MACROINDICATORS 221
TABLE 211 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY 2022–2029 (USD MILLION) 222
TABLE 212 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT 2022–2029 (USD MILLION) 222
TABLE 213 EUROPE: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION) 222
TABLE 214 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY 2022–2029 (USD MILLION) 223
TABLE 215 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS BY TYPE, 2022–2029 (USD MILLION) 223
TABLE 216 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022–2029 (USD MILLION) 224
TABLE 217 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS 2022–2029 (USD MILLION) 224
TABLE 218 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 225
TABLE 219 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN 2022–2029 (USD MILLION) 225
TABLE 220 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER 2022–2029 (USD MILLION) 225
TABLE 221 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT 2022–2029 (USD MILLION) 227
TABLE 222 GERMANY: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION) 227
TABLE 223 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY 2022–2029 (USD MILLION) 227
TABLE 224 GERMANY: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS BY TYPE, 2022–2029 (USD MILLION) 228
TABLE 225 GERMANY: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022–2029 (USD MILLION) 228
TABLE 226 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS 2022–2029 (USD MILLION) 229
TABLE 227 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 229
TABLE 228 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN 2022–2029 (USD MILLION) 230
TABLE 229 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY END USER 2022–2029 (USD MILLION) 230
TABLE 230 UK: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT 2022–2029 (USD MILLION) 231
TABLE 231 UK: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE 2022–2029 (USD MILLION) 232
TABLE 232 UK: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY 2022–2029 (USD MILLION) 232
TABLE 233 UK: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS, BY TYPE, 2022–2029 (USD MILLION) 232
TABLE 234 UK: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS BY TYPE, 2022–2029 (USD MILLION) 233
TABLE 235 UK: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS 2022–2029 (USD MILLION) 233
TABLE 236 UK: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA 2022–2029 (USD MILLION) 234
TABLE 237 UK: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN 2022–2029 (USD MILLION) 234
TABLE 238 UK: THERAPEUTIC DRUG MONITORING MARKET, BY END USER 2022–2029 (USD MILLION) 234
TABLE 239 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT 2022–2029 (USD MILLION) 236
TABLE 240 FRANCE: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE 2022–2029 (USD MILLION) 236
TABLE 241 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY 2022–2029 (USD MILLION) 236
TABLE 242 FRANCE: THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAYS BY TYPE, 2022–2029 (USD MILLION) 237
TABLE 243 FRANCE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2022–2029 (USD MILLION) 237
TABLE 244 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS 2022–2029 (USD MILLION) 238
TABLE 245 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 238
TABLE 246 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN 2022–2029 (USD MILLION) 239
TABLE 247 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER 2022–2029 (USD MILLION) 239
TABLE 248 ITALY: CANCER INCIDENC